Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)

06/16/2021 | 04:32pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

Shareholders of record at the close of business on April 12, 2021 were entitled to vote 62,325,125 shares of common stock at the Annual Meeting. A total of 46,071,587 shares (73.9%) were represented at the Annual Meeting in person or by proxy. Set forth below is a brief description of each matter voted upon at the Annual Meeting and the final voting results for each matter.

The following individuals were elected to serve as directors by the vote set

forth below. Drs. Thomas F. Bumol, Gregory A. Demopulos, and Leroy E. Hood (1) were elected as Class III directors, each to serve until the 2024 Annual

    Meeting of Shareholders, or, in each case, until his successor is duly
    elected and qualified, or until his earlier death, resignation or removal.







                                For        Against     Abstain   Broker Non-Votes

Thomas F. Bumol, Ph.D. 27,554,017 2,718,868 79,291 15,719,411 Gregory A. Demopulos, M.D. 28,280,206 1,857,471 214,499 15,719,411 Leroy E. Hood, M.D., Ph.D. 19,966,295 10,307,337 78,544 15,719,411

Shareholders approved an amendment to the Omeros Corporation 2017 Omnibus (2) Incentive Compensation Plan to increase the number of authorized shares by

    the vote set forth below.





   For        Against    Abstain   Broker Non-Votes
22,621,598   7,543,739   186,839      15,719,411





Shareholders ratified the appointment of Ernst & Young LLP as Omeros' (3) independent registered public accounting firm for the fiscal year ending

    December 31, 2021 by the vote set forth below.





   For        Against    Abstain   Broker Non-Votes
44,784,520   1,141,578   145,489          -

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.






Exhibit Number Description
10.1             Omeros Corporation 2017 Omnibus Incentive Compensation Plan (as
               amended and restated effective June 11, 2021)
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses

All news about OMEROS CORPORATION
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
06/15OMEROS' : Narsoplimab pivotal trial data shared in oral presentation at 2021 ann..
AQ
06/14OMEROS : rsquo; Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 20..
BU
06/14Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentat..
CI
06/10OMEROS : Announces Publication Detailing the Mechanism of Action of PDE7 In Nico..
BU
06/09OMEROS : to Present at the BofA 2021 Napa BioPharma Virtual Conference
BU
06/09OMEROS : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-..
MT
06/09OMEROS : Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
BU
More news
Financials (USD)
Sales 2021 107 M - -
Net income 2021 -128 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -7,45x
Yield 2021 -
Capitalization 922 M 922 M -
EV / Sales 2021 11,0x
EV / Sales 2022 7,07x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 14,79 $
Average target price 27,00 $
Spread / Average Target 82,6%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION3.54%922
GILEAD SCIENCES, INC.20.25%87 579
BIONTECH SE283.45%75 497
WUXI APPTEC CO., LTD.38.94%70 844
REGENERON PHARMACEUTICALS21.38%60 387
VERTEX PHARMACEUTICALS-15.22%51 872